Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Wesolowski

Showing results (41-50 of 136) with videos related to

Pageof 14
Sort By:
Breast Cancer Research and Treatment|April 12, 2011
Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancerMin Han Tan, Sarmishtha De, Gurkan Bebek, et al.
British Journal of Cancer|May 27, 2021
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumoursGeoffrey I Shapiro, Robert Wesolowski, Craig Devoe, et al.
Breast Cancer Research and Treatment|April 5, 2017
Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patientsScott M Monfort, Xueliang Pan, Robyn Patrick, et al.
The Oncologist|March 4, 2015
Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trialsMellissa Hicks, Erin R Macrae, Mahmoud Abdel-Rasoul, et al.
Investigational New Drugs|June 5, 2014
A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancerMeng Zhao, Xueliang Pan, Rachel Layman, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 19, 2020
The impact of granulocyte colony-stimulating factor use in patients with metastatic breast cancer treated with palliative chemotherapy: a single-institution retrospective reviewLuay Mousa, Julie A Stephens, Michael Berger, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|July 2, 2019
Pathological complete response rates with pertuzumab-based neoadjuvant chemotherapy in breast cancer: A single-center experienceChristina M Matthews, Kristen Nymberg, Michael Berger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 27, 2019
Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid TumorsTanios Bekaii-Saab, Robert Wesolowski, Daniel H Ahn, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 8, 2026
Safely Stopping Premedications in Patients Receiving Paclitaxel: A Randomized TrialMichael Berger, Maryam Lustberg, Paul J Novotny, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 19, 2014
Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reactionMichael J Berger, Craig Vargo, Mary Vincent, et al.
Pageof 14

Showing results (41-50 of 136) with videos related to

Sort By:
Pageof 14
Breast Cancer Research and Treatment|April 12, 2011
Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancerMin Han Tan, Sarmishtha De, Gurkan Bebek, et al.
British Journal of Cancer|May 27, 2021
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumoursGeoffrey I Shapiro, Robert Wesolowski, Craig Devoe, et al.
Breast Cancer Research and Treatment|April 5, 2017
Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patientsScott M Monfort, Xueliang Pan, Robyn Patrick, et al.
The Oncologist|March 4, 2015
Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trialsMellissa Hicks, Erin R Macrae, Mahmoud Abdel-Rasoul, et al.
Investigational New Drugs|June 5, 2014
A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancerMeng Zhao, Xueliang Pan, Rachel Layman, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 19, 2020
The impact of granulocyte colony-stimulating factor use in patients with metastatic breast cancer treated with palliative chemotherapy: a single-institution retrospective reviewLuay Mousa, Julie A Stephens, Michael Berger, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|July 2, 2019
Pathological complete response rates with pertuzumab-based neoadjuvant chemotherapy in breast cancer: A single-center experienceChristina M Matthews, Kristen Nymberg, Michael Berger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 27, 2019
Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid TumorsTanios Bekaii-Saab, Robert Wesolowski, Daniel H Ahn, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 8, 2026
Safely Stopping Premedications in Patients Receiving Paclitaxel: A Randomized TrialMichael Berger, Maryam Lustberg, Paul J Novotny, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 19, 2014
Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reactionMichael J Berger, Craig Vargo, Mary Vincent, et al.
Pageof 14